Clinical Trial of Endorectal Amifostine for Radioprotection in Patients with Prostate Cancer: Rationale and Early Results

Seminars in Oncology

Volumn 30, Issue 6 SUPPL. 18, 2003, Pages 63-67

  Ménard, Cynthia ^a   Camphausen, Kevin ^b   Muanza, Thierry ^b   Sears Crouse, Nancy ^b   Smith, Sharon ^b   Ben Josef, Edgar ^b   Coleman, C Norman ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; LEUPRORELIN; LOPERAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; BEAM THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIARRHEA; FOLLOW UP; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; RADIATION DOSE; RADIATION PROTECTION; RECTOSCOPY; RECTUM DISEASE;

EID: 1642517270     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.11.016     Document Type: Conference Paper

References (23)

1. Cancer Statistics 2003: Atlanta, GA, American Cancer Society, 2003
2. Fuks Z, Leibel SA, Wallner KE, et al: The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 1251 implantation. Int J Radiat Oncol Biol Phys 21:537-547, 1991
3. Horwitz EM, Hanlon AL, Pinover WH, et al: Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer 92: 1281-1287, 2001
4. Pollack A, Smith LG, von Eschenbach AC: External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48:507-512, 2000
5. Zelefsky MJ, Fuks Z, Hunt M, et al: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166: 876-881, 2001
6. Pollack A, Zagars GK, Smith LG, et al: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904-3911, 2000
7. Michalski JM, Purdy JA, Winter K, et al: Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46:391-402, 2000
8. Pollack A, Zagars GK, Starkschall G, et al: Conventional vs. conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34:555-564, 1996
9. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase 11 study. J Clin Oncol 18:2226-2233, 2000
10. Kligerman MM, Blumberg AL, Glick JH, et al: Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum. Cancer Clin Trials 4:469-474, 1981
11. Kouvaris J, Kouloulias V, Malas E, et al: Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors: A phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol 179:167-174, 2003
12. Ben-Josef E, Mesina J, Shaw LM, et al: Topical application of WR-2721 achieves high concentrations in the rectal wall. Radiat Res 143:107-110, 1995
13. Ben-Josef E, Han S, Tobi M, et al: A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. Int J Radiat Oncol Biol Phys 53: 1160-1164, 2002
14. Wei JT, Dunn RL, Litwin MS, et al: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899-905, 2000
15. Wachter S, Gerstner N, Goldner G, et al: Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma. Radiother Oncol 54:11-19, 2000
16. France HG Jr, Jirtle RL, Mansbach CM 11: Intracolonic WR 2721 protection of the rat colon from acute radiation injury. Gastroenterology 91:644-650, 1986
17. Delaney JP, Bonsack ME, Felemovicius I: Radioprotection of the rat small intestine with topical WR-2721. Cancer 74:2379-2384, 1994
18. Halberg FE, LaRue SM, Rayner AA, et al: Intraoperative radiotherapy with localized radioprotection: Diminished duodenal toxicity with intraluminal WR2721. Int J Radiat Oncol Biol Phys 21:1241-1246, 1991
19. Montana GS, Anscher MS, Mansback CM II, et al: Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis: A phase I/Il trial. Cancer 69:2826-2830, 1992
20. Zelefsky MJ, Fuks Z, Wolfe T, et al: Locally advanced prostatic cancer: Long-term toxicity outcome after three-dimensional conformal radiation therapy-A dose-escalation study. Radiology 209:169-174, 1998
21. Storey MR, Pollack A, Zagars G, et al: Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48:635-642, 2000
22. Michalski JM, Winter K, Purdy JA, et al: Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 56:192-198, 2003
23. Wei JT, Dunn RL, Sandler HM, et al: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20:557-566, 2002